24Purpose: The retina is highly metabolically active, suggesting that metabolic 25 dysfunction could underlie many retinal degenerative diseases. Nicotinamide 26 adenine dinucleotide (NAD + ) is a cofactor and a co-substrate in several cellular 27 energetic metabolic pathways. Maintaining NAD + levels may be therapeutic in 28 retinal disease since retinal NAD + levels decline with age and during retinal 29 damage or degeneration. The purpose of this study was to investigate whether 30 systemic treatment with nicotinamide riboside (NR), a NAD + precursor, is 31 protective in disparate models of retinal damage or degeneration. 32 33 Methods: Three mouse models of retinal degeneration were tested: an albino 34 mouse model of light-induced retinal degeneration (LIRD) and two models of 35 retinitis pigmentosa (RP), including a mouse line deficient in interphotoreceptor 36 binding protein (IRBP) gene expression (IRBP KO), and a naturally-occuring 37 cGMP phosphodiesterase 6b mutant mouse model of RP (the Pde6b rd10 mouse). 38 Mice were intraperitoneally (IP) injected with PBS or NR at various times relative 39 to damage or degeneration onset. One to two weeks later, retinal function was 40 assessed by electroretinograms (ERGs) and retinal morphology was assessed 41 by optical coherence tomography (OCT). Afterwards, retina sections were H&E 42 stained for morphological analysis or by terminal deoxynucleiotidyl transferase 43 dUTP nick and labeling (TUNEL). Retinal NAD + /NADH levels were enzymatically 44 assayed. 45 46 3 Results: The retinal degeneration models exhibited significantly suppressed 47 retinal function, and where examined, severely disrupted photoreceptor cell layer 48 and significantly decreased numbers of nuclei and increased accumulation of 49 DNA breaks as measured by TUNEL-labeled cells in the outer nuclear layer 50 (ONL). These effects were prevented by various NR treatment regimens. IP 51 treatment with NR also resulted in increased levels of NAD + in retina. 52 53 Conclusions: This is the first study to report protective effects of NR treatment in 54 mouse models of retinal degeneration. The positive outcomes in several models, 55 coupled with human tolerance to NR dosing, suggest that maintaining retinal 56 NAD + via systemic NR treatment should be further explored for clinical relevance. 57 58 59 60 61 62 63 64 65 66 67 68 0.00039 0.00374 0.058 0.961 25.3 Flash intensity (cd s/m 2 ) Flash intensity (cd s/m 2 ) Flash intensity (cd*s/m 2 ) * * * * 0.00039 0.00374 0.058 0.961 25.3 Flash intensity (cd s/m 2 ) Flash intensity (cd s/m 2 )